Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/29085
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Antony A. | en |
dc.contributor.author | Connelly K. | en |
dc.contributor.author | De Silva T. | en |
dc.contributor.author | Eades L. | en |
dc.contributor.author | Tillett W. | en |
dc.contributor.author | Morand E. | en |
dc.contributor.author | Ayoub S. | en |
dc.date.accessioned | 2021-05-14T09:48:55Z | en |
dc.date.available | 2021-05-14T09:48:55Z | en |
dc.date.copyright | 2020 | en |
dc.date.created | 20200907 | en |
dc.date.issued | 2020-09-07 | en |
dc.identifier.citation | Arthritis Care and Research. 72 (9) (pp 1189-1195), 2020. Date of Publication: 01 Sep 2020. | en |
dc.identifier.issn | 2151-464X | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/29085 | en |
dc.description.abstract | Objective: To determine health perceptions of patients with rheumatic diseases in the early phase of the coronavirus disease 2019 (COVID-19) pandemic. Method(s): Rheumatology patients at a single center received via text message the Australian Rheumatology Association COVID-19 information sheet and an invitation to participate in a deidentified survey. Patient concerns regarding risks conferred by their rheumatologic disease or medications, impact of receiving the information sheet on the likelihood of staying on medication, and acceptance of telehealth were ascertained. Result(s): A total of 2,630 patients received the text message, and the survey response rate was 21% (n = 550). The mean +/- SD age of the participants was 52 +/- 15.2 years, and 75.3% were female. Participants' highest ranked concern was that their medications would increase the severity of their COVID-19 symptoms (76.1%). The highest levels of concern were seen in patients taking combination conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and/or a biologic/targeted synthetic DMARD. There was no association between prednisolone dose and concern. While 63% of patients planned to continue their antirheumatic medications, a further 30% were more likely to continue taking their medications because of receiving the information. Telehealth was acceptable to 98.4% of patients, but 28.1% felt this was only appropriate while infection control measures were in place. Conclusion(s): Concerns regarding the risk of COVID-19 among patients taking antirheumatic drugs are common. Proactive dissemination of information is needed to address misconceptions related to medication risk, improve medication adherence, and minimize the risk of flares. Telehealth is acceptable to most patients during the COVID-19 pandemic.Copyright © 2020, American College of Rheumatology | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | John Wiley and Sons Inc. (P.O.Box 18667, Newark NJ 07191-8667, United States) | en |
dc.relation.ispartof | Arthritis Care and Research | en |
dc.subject.mesh | psoriatic arthritis | - |
dc.subject.mesh | rheumatic disease | - |
dc.subject.mesh | rheumatoid arthritis | - |
dc.subject.mesh | rheumatology | - |
dc.subject.mesh | scleroderma | - |
dc.subject.mesh | social acceptance | - |
dc.subject.mesh | spondylarthritis | - |
dc.subject.mesh | systemic lupus erythematosus | - |
dc.subject.mesh | telehealth | - |
dc.subject.mesh | therapeutic misconception | - |
dc.subject.mesh | vasculitis | - |
dc.subject.mesh | abatacept | - |
dc.subject.mesh | azathioprine | - |
dc.subject.mesh | cyclophosphamide | - |
dc.subject.mesh | cyclosporine | - |
dc.subject.mesh | hydroxychloroquine | - |
dc.subject.mesh | Janus kinase inhibitor | - |
dc.subject.mesh | leflunomide | - |
dc.subject.mesh | methotrexate | - |
dc.subject.mesh | mycophenolic acid | - |
dc.subject.mesh | nonsteroid antiinflammatory agent | - |
dc.subject.mesh | prednisolone | - |
dc.subject.mesh | rituximab | - |
dc.subject.mesh | salazosulfapyridine | - |
dc.subject.mesh | secukinumab | - |
dc.subject.mesh | tacrolimus | - |
dc.subject.mesh | tocilizumab | - |
dc.subject.mesh | tumor necrosis factor inhibitor | - |
dc.subject.mesh | ustekinumab | - |
dc.subject.mesh | infection control | - |
dc.subject.mesh | coronavirus disease 2019 | - |
dc.subject.mesh | disease course | - |
dc.subject.mesh | drug use | - |
dc.subject.mesh | health survey | - |
dc.subject.mesh | medical information | - |
dc.subject.mesh | pandemic | - |
dc.subject.mesh | patient participation | - |
dc.subject.mesh | patient risk | - |
dc.subject.mesh | perception | - |
dc.title | Perspectives of Patients With Rheumatic Diseases in the Early Phase of COVID-19. | en |
dc.type | Article | en |
dc.identifier.affiliation | Monash University - School of Clinical Sciences at Monash Health | - |
dc.identifier.affiliation | Rheumatology | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1002/acr.24347 | - |
dc.publisher.place | United States | en |
dc.identifier.pubmedid | 32526068 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32526068] | en |
dc.identifier.source | 2006019805 | en |
dc.identifier.institution | (Antony, Connelly, Ayoub, Morand) School of Clinical Sciences, Monash University, and Monash Health, VIC, Australia (De Silva, Eades) Monash Health, VIC, Australia (Tillett) Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, and University of Bath, Bath, United Kingdom | en |
dc.description.address | A. Antony, School of Clinical Sciences, Monash University, and Monash Health, VIC, Australia. E-mail: anna.antony@monash.edu | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2020 Elsevier B.V., All rights reserved. | en |
dc.identifier.authoremail | Antony A.; anna.antony@monash.edu | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
crisitem.author.dept | Rheumatology | - |
crisitem.author.dept | Rheumatology | - |
crisitem.author.dept | Rheumatology | - |
crisitem.author.dept | Centre for Inflammatory Diseases at Monash Health | - |
crisitem.author.dept | Rheumatology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.